Skip to search formSkip to main contentSkip to account menu

Ibrutinib

Known as: 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one, 2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)- 
An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration… 
National Institutes of Health

Related topics

Related topics

6 relations
Ibrutinib 140 MG Oral CapsuleIbrutinib 140 MG Oral Capsule [Imbruvica]NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Narrower (1)

Imbruvica

Broader (1)

PCI 32765

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
BACKGROUND Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have… 
Highly Cited
2019
Highly Cited
2019
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
The Bruton tyrosine kinase (BTK) inhibitor ibrutinib improves patient outcomes in chronic lymphocytic leukemia (CLL); however… 
Highly Cited
2018
Highly Cited
2018
Ibrutinib plus Venetoclax for the Treatment of Mantle‐Cell Lymphoma
BACKGROUND Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as monotherapy in the treatment of… 
Review
2017
Review
2017
Ibrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an effective therapeutic agent for… 
Highly Cited
2014
Highly Cited
2014
Ibrutinib resistance in chronic lymphocytic leukemia.
Ibrutinib, a Bruton's tyrosine kinase inhibitor, is active in CLL, but resistance may emerge. The authors observed the emergence… 
Highly Cited
2014
Highly Cited
2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has outstanding activity in patients with chronic lymphocytic leukemia… 
Highly Cited
2014
Highly Cited
2014
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.
To the editor: Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase (BTK) with promising activity in CD20+ B-cell… 
Highly Cited
2014
Highly Cited
2014
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
The BTK (Bruton’s tyrosine kinase) inhibitor ibrutinib is associated with an increased risk of bleeding. A previous study… 
Review
2013
Review
2013
Ibrutinib and novel BTK inhibitors in clinical development
Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved… 
Review
2013
Review
2013
Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment
Disease Overview: Chronic lymphocytic leukemia (CLL) is the commonest leukemia in western countries. The disease typically occurs… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)